Bristol-Myers Squibb Co
NYSE:BMY
Bristol-Myers Squibb Co
NYSE:BMY
Price:
44.03 USD
-0.18%
Market Closed
Updated:
May 18, 2024
Bristol-Myers Squibb Co
Total Receivables
|
Bristol-Myers Squibb Co
Total Receivables Peer Comparison
Comparables:
JNJ
PFE
MRK
ZTS
LLY
Competitive Total Receivables Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Receivables
$14.1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
20%
|
CAGR 10-Years
17%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Receivables
$14.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Receivables
$15.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Receivables
$12.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Total Receivables
$1.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Receivables
$10B
|
CAGR 3-Years
15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
See Also
What is Bristol-Myers Squibb Co's Total Receivables?
Total Receivables
14.1B
USD
14.1B
USD
Based on the financial report for Mar 31, 2024, Bristol-Myers Squibb Co's Total Receivables amounts to 14.1B USD.
What is Bristol-Myers Squibb Co's Total Receivables growth rate?
Total Receivables CAGR 10Y
17%
17%
Over the last year, the Total Receivables growth was 5%. The average annual Total Receivables growth rates for Bristol-Myers Squibb Co have been 18% over the past three years , 20% over the past five years , and 17% over the past ten years .
You don't have any saved screeners yet
